Welcome to the ISCB Community News Blog

This blog collects news, announcements or other information which could be of interest to our ISCB members. We are a group ISCB members who volunteer to populate this blog on a regular basis. In case you want to become an "ISCB-News Reporter" yourself, let us know: contact ISCB
Don't repost copyrighted content! The guidelines are:
- Include a link to the source page
- Include a short summary about the article. You can quote up to ONE paragraph from the original story, but not more
- Don't repost an entire articles originating from another source
- Never post content without attribution — always include the source

To post a news, please use this form.

Wednesday, January 27, 2016

ISCB Responds to New England Journal of Medicine Article

The recent editorial by Drs. Longo and Drazen in the New England Journal of Medicine (NEJM) [1] has stirred up quite a bit of controversy. As Executive Officers of the International Society of Computational Biology, Inc. (ISCB), we express our deep concern about the restrictive and potentially damaging opinions voiced in this editorial. While some of the concerns voiced by the authors of the editorial are worth considering, large parts of the statement purport an obsolete view of hegemony over data that is neither in line with today's spirit of open access nor furthering an atmosphere where the potential of data can be fully realized.

We acknowledge that the additional comment on the editorial [2] eases some of the polemics, unfortunately without addressing some of the core issues. We still feel, however, that we need to contrast the opinion voiced in the editorial with what we consider the axioms of our scientific society, statements that lead into a fruitful future of data-driven science:

• Data produced with public money should be public in benefit of the science and society
• Restrictions to the use of public data hamper science and slow progress
• Open data is the best way to combat fraud and misinterpretations

Current large data collections proceed from many sources are continually accumulated and require a variety of analytical approaches. Data generation and data analysis overlap in time and are continually updated with new data sets produced by new techniques and new analysis methodologies. Furthermore, in many cases current science functions in consortia in which scientists collaborate toward common goals while preserving their own scientific objectives. Dividing scientists into data providers and data analysts is simplistic and gives a misleading impression of the actual state of biological and biomedical science.

We very much support collaboration between disciplines, including experimental and clinical as well as bioinformatics, as the best way forward to address complex biological problems. But this collaboration cannot be based on imposed restrictions to data access and cannot be contained in professional silos. (The use of expressions such as "research parasites" clearly does not help.)

Many bio-communities have made significant progress by endorsing open data policies and, gratefully, public funding agencies have connected to the spirit that they are distributing taxpayers' money to science and that, therefore, the data that are generated in the course belong to the public. It is, perhaps, natural that some areas of biomedical research are slow in adopting these policies. History and the confidential nature of the relevant data are surely one of the reasons. However, in our opinion data hegemony is another, a reason that has to be overcome. The sooner these barriers to progress are removed the sooner the patients will benefit from the current flourishing of biomedical research.

1. Longo, D.L. and J.M. Drazen, Data Sharing. N Engl J Med, 2016. 374(3): p. 276-7.
2. Drazen, J.M., Data Sharing and the Journal. New Engl J Med.

Respectfully submitted by the International Society for Computational Biology's Executive Committee,

Alfonso Valencia, President
Bonnie Berger, Vice President
Terry Gaasterland, Vice President
Thomas Lengauer, Vice President
Christine Orengo, Vice President
Bruno Gaeta, Treasurer
Scott Markel, Secretary


Contact Person: Executive Office (executive.office@iscb.org)

6 comments:

  1. Sufferers with muscular skeletal problems will see marked improvement after the first numerous remedies. rocky mountain acupuncture and Chinese medicine Denver co stimulated the restore of broken and infected tissue. outcomes are heavily dependent on patient compliance and regularly restrict on no longer re-injuring the area throughout treatment.

    ReplyDelete
  2. CBD and hemp oil online shopping. CBD and hemp oil products for sale online. Shop for CBD and hemp oil now!

    ReplyDelete
  3. Considerably progressively significant, if the clinic based doctor masterminds to have the patient's consideration accepted by another doctor, the patient should completely comprehend this change, and it ought to be painstakingly reported. https://rxasap.mobi/fr/

    ReplyDelete
  4. Tesni Pharma includes a team of qualified and experienced professionals who thoroughly analyze and check the medicines and test them for quality, safety and purity. With many years of experience in the sector, our professionals have the ability to formulate some effective as well as clean medicines. http://tesnipharma.com

    ReplyDelete
  5. CENFORCE-100 Chewable (Sildenafil Citrate 100mg) Cenforce 100mg chewable is one of the best alternatives to Kamagra Chewable tabs starts to work quicker than any other Sildenafil based pill: http://cenforceonline.net/it/comprare-centurion-cenforce-viagra.html

    ReplyDelete
  6. We are a company dedicated to the Area of Traumatology. Official Distributors DePuy. Osteosynthesis Materials, Atreoscopy, Laproscopy, Hand Surgery, Neurosurgery, Plastic Surgery, and Medical Surgical Instumental

    ReplyDelete